Applications of bio-predictive dissolution tools for the development of solid oral dosage forms: current industry experience

References

• Shono Y, Jantratid E, Kesisoglou F, et al. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm. 2010;76(1):95–104.
   PubMedGoogle Scholar
• Culen M, Rezacova A, Jampilek J, et al. Designing a dynamic dissolution method: a review of instrumental options and corresponding physiology of stomach and small intestine. J Pharm Sci. 2013;102(9):2995–3017.
   PubMedGoogle Scholar
• Food and Drug Administration. Guidance for industry: the use of physiologically based pharmacokinetic analyses - biopharmaceutics applications for oral drug product development, manufacturing changes, and controls. 2020.
   Google Scholar
• Nguyen MA, Flanagan T, Brewster M, et al. A survey on IVIVC/IVIVR development in the pharmaceutical industry - Past experience and current perspectives. Eur J Pharm Sci. 2017;102:1–13.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry: extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations. 1997.
   Google Scholar
• Khaled AAA, Pervaiz K, Karim S, et al. Development of in vitro-in vivo correlation for encapsulated metoprolol tartrate. Acta Poloniae Pharmaceutica. 2013;70:743–747.
   PubMed Web of Science ®Google Scholar
• Jantratid E, Maio VD, Ronda E, et al. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci. 2009;37(3-4):434–441.
   PubMed Web of Science ®Google Scholar
• Turner S, Federici C, Hite M, et al. Formulation development and human in vitro-in vivo correlation for a novel, monolithic controlled-release matrix system of high load and highly water-soluble drug niacin. Drug Dev Ind Pharm. 2004;30(8):797–807.
   PubMed Web of Science ®Google Scholar
• Subburayalu R, Kunchitharatham J, Devi T. Application of biorelevant dissolution tests to the prediction of in vivo performance of clopidogrel extended release mini tablets filled in capsules. Indo Am J Pharmac Res. 2014;4:160–170.
   Google Scholar
• Murtaza G, Ahmad M, Akhtar N. Biowaiver study of oral tabletted ethylcellulose microcapsules of a BCS class I drug. Bull Chem Soc Eth. 2009;23(2):175–186.
   Google Scholar
• Mendes T, Simon A, Menezes JCV, et al. Development of USP apparatus 3 dissolution method with IVIVC for extended release tablets of metformin hydrochloride and development of a generic formulation. Chem Pharm Bull. 2019;67(1):23–31.
   PubMedGoogle Scholar
• Bezerra K, Pinto EC, Cabral LM, et al. Development of a dissolution method for gliclazide modified-release tablets using USP apparatus 3 with in vitro-in vivo correlation. Chem Pharm Bull. 2018;66(7):701–707.
   PubMedGoogle Scholar
• Grundy JS, Anderson KE, Rogers JA, et al. Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. II. Improved in vitro-in vivo correlation using a two-phase dissolution test. J Control Release. 1997;48(1):9–17.
   Google Scholar
• Ruiz Picazo A, Martinez-Martinez MT, Colon-Useche S, et al. In vitro dissolution as a tool for formulation selection: telmisartan Two-Step IVIVC. Mol Pharm. 2018;15(6):2307–2315.
   PubMedGoogle Scholar
• Emara LH, el-Menshawi BS, Estefan MY. In vitro-in vivo correlation and comparative bioavailablity of vincamine in prolonged-release preparations. Drug Dev Ind Pharm. 2000;26(3):243–251.
   PubMed Web of Science ®Google Scholar
• Mahayni H, Rekhi GS, Uppoor RS, et al. Evaluation of "external" predictability of an in vitro-in vivo correlation for an extended-release formulation containing metoprolol tartrate. J Pharm Sci. 2000;89(10):1354–1361.
   PubMed Web of Science ®Google Scholar
• Kakhi M, Marroum P, Chittenden J. Analysis of level a in vitro-in vivo correlations for an extended-release formulation with limited bioavailability. Biopharm Drug Dispos. 2013;34(5):262–277.
   PubMedGoogle Scholar
• Ghosh A, Bhaumik UK, Bose A, et al. Extended release dosage form of glipizide: development and validation of a level a in vitro-in vivo correlation. Biol Pharm Bull. 2008;31(10):1946–1951.
   PubMed Web of Science ®Google Scholar
• Takka S, Sakr A, Goldberg A. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets. J Control Release. 2003;88(1):147–157.
   PubMed Web of Science ®Google Scholar
• Sarfraz M, Ahmad M, Sarfraz A. A systematic approach to develop level a, in-vitro and in-vivo correlation (IVIVC)-ketoprofen bcs class II drug example. Paki J Sci Industr Res. 2012;55(1):15–26.
   Google Scholar
• Dutta S, Qiu Y, Samara E, et al. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a level a in vitro-in vivo correlation (IVIVC). J Pharm Sci. 2005;94(9):1949–1956.
   PubMedGoogle Scholar
• Eddington ND, Marroum P, Uppoor R, et al. Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. Pharm Res. 1998;15(3):466–473.
   PubMed Web of Science ®Google Scholar
• Patel N, Turner D, Polak S, et al. Mechanistic deconvolution using the ADAM Model: part 1. Establishing mechanistic IVIVC for controlled release formulations of the high extraction BCS Class I drug metoprolol: comparison with conventional IVIVC models. AAPS Annual Meeting and Exposition. 2012.
   Google Scholar
• Eddington ND. In vitro in vivo correlation with metoprolol extended release tablets using two different releasing formulations: an internal validation evaluation. Inter J Generic Drugs IVIVC Series Part I. 2000;3:417–429.
   Google Scholar
• Sirisuth N, Eddington ND. Systematic method for the development and validation of an IVIVC metoprolol and naproxen drug examples. Inter J Generic Drugs IVIVC Series Part III. 2001;4:250–258.
   Google Scholar
• Sirisuth N, Augsburger LL, Eddington ND. Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation. Biopharm Drug Dispos. 2002;23(1):1–8.
   PubMedGoogle Scholar
• Yamashita F, Fujita A, Zhang X, et al. Computer-based evolutionary search for a nonlinear conversion function for establishing in vitro-in vivo correlation (IVIVC) of oral drug formulations. Drug Metab Pharmacokinet. 2012;27(3):280–285.
   PubMedGoogle Scholar
• Mirza T, Bykadi SA, Ellison CD, et al. Use of in vitro-in vivo correlation to predict the pharmacokinetics of several products containing a BCS class 1 drug in extended release matrices. Pharm Res. 2013;30(1):179–190.
   PubMedGoogle Scholar
• Soto E, Haertter S, Koenen-Bergmann M, et al. Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations. Pharm Res. 2010;27(2):340–349.
   PubMed Web of Science ®Google Scholar
• Kortejarvi H, Malkki J, Marvola M, et al. Level a in vitro-in vivo correlation (IVIVC) model with bayesian approach to formulation series. J Pharm Sci. 2006;95(7):1595–1605.
   PubMedGoogle Scholar
• Mohamed M-EF, Trueman S, Othman AA, et al. Development of in Vitro-In vivo correlation for upadacitinib Extended-Release tablet formulation. Aaps J. 2019;21(6):1–9.
   Google Scholar
• Mittapalli RK, Nuthalapati S, Delke DeBord AE, et al. Development of a level a in vitro-in vivo correlation for veliparib (ABT-888) extended release tablet formulation. Pharm Res. 2017;34(6):1187–1192.
   PubMedGoogle Scholar
• Xu J, Lin Y, Zawaneh PN, et al. Prediction of in vivo performance of oral extended release formulations prior to clinical evaluation: a case study for enteric coated polymeric beads formulation. Eur J Pharm Biopharm. 2021;158:222–232.
   PubMedGoogle Scholar
• Vuletic L, Khan MZI, Spoljaric D, et al. Development of a clinically relevant dissolution method for metaxalone immediate release formulations based on an IVIVC model. Pharm Res. 2018;35(8):1–13.
   Google Scholar
• Kesisoglou F, Chung J, van Asperen J, et al. Physiologically based absorption modeling to impact biopharmaceutics and formulation strategies in drug Development-Industry case studies. J Pharm Sci. 2016;105(9):2723–2734.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Mitra A. Application of absorption modeling in rational design of drug product under quality-by-Design paradigm. Aaps J. 2015;17(5):1224–1236.
   PubMedGoogle Scholar
• European Medicines Agency. Guideline on quality of oral modified release products. 2014.
   Google Scholar
• Ilic M, Djuris J, Kovacevic I, et al. In vitro - in silico - in vivo drug absorption model development based on mechanistic gastrointestinal simulation and artificial neural networks: nifedipine osmotic release tablets case study. Eur J Pharm Sci. 2014;62:212–218.
   PubMed Web of Science ®Google Scholar
• Kambayashi A, Dressman JB. An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene. Eur J Pharm Biopharm. 2013;84(1):200–207.
   PubMedGoogle Scholar
• Jamei M, Abrahamsson B, Brown J, et al. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary. Eur J Pharm Biopharm. 2020;155:55–68.
   PubMed Web of Science ®Google Scholar
• Juenemann D, Jantratid E, Wagner C, et al. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Eur J Pharm Biopharm. 2011;77(2):257–264.
   PubMedGoogle Scholar
• Litou C, Patel N, Turner DB, et al. Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states. Eur J Pharm Sci. 2019;138:105031.
   PubMed Web of Science ®Google Scholar
• Kostewicz ES, Abrahamsson B, Brewster M, et al. In vitro models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:342–366.
   PubMed Web of Science ®Google Scholar
• Butler J, Hens B, Vertzoni M, et al. In vitro models for the prediction of in vivo performance of oral dosage forms: recent progress from partnership through the IMI OrBiTo collaboration. Eur J Pharm Biopharm. 2019;136:70–83.
   PubMedGoogle Scholar
• Takano R, Sugano K, Higashida A, et al. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res. 2006;23(6):1144–1156.
   PubMed Web of Science ®Google Scholar
• Lu ATK, Frisella ME, Johnson KC. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res. 1993;10(9):1308–1314.
   PubMed Web of Science ®Google Scholar
• Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Inter J Pharma. 1989;51(1):9–17.
   Web of Science ®Google Scholar
• Kesisoglou F, Wu Y. Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J. 2008;10(4):516–525.
   PubMedGoogle Scholar
• Mitra A, Zhu W, Kesisoglou F. Physiologically based absorption modeling for amorphous solid dispersion formulations. Mol Pharm. 2016;13(9):3206–3215.
   PubMedGoogle Scholar
• Food and Drug Administration. Guidance for Industry: food-effect bioavailability and fed bioequivalence studies. 2002.
   Google Scholar
• O'Shea JP, Holm R, O'Driscoll CM, et al. Food for thought: formulating away the food effect - a PEARRL review. J Pharm Pharmacol. 2019;71(4):510–535.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on the investigation of drug interactions. 2013.
   Google Scholar
• Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23.
   PubMed Web of Science ®Google Scholar
• Fleisher D, Li C, Zhou Y, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet. 1999;36(3):233–254.
   PubMed Web of Science ®Google Scholar
• Heimbach T, Xia B, Lin T-h, et al. Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data. AAPS J. 2013;15(1):143–158.
   PubMedGoogle Scholar
• Gu CH, Li H, Levons J, et al. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res. 2007;24(6):1118–1130.
   PubMed Web of Science ®Google Scholar
• Mathias N, Xu Y, Vig B, et al. Food effect in humans: predicting the risk through in vitro dissolution and in vivo pharmacokinetic models. AAPS J. 2015;17(4):988–998.
   PubMedGoogle Scholar
• Wagner C, Jantratid E, Kesisoglou F, et al. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model. Eur J Pharm Biopharm. 2012;82(1):127–138.
   PubMed Web of Science ®Google Scholar
• Kostewicz ES, Wunderlich M, Brauns U, et al. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol. 2004;56(1):43–51.
   PubMedGoogle Scholar
• Sauron R, Wilkins M, Jessent V, et al. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int J Clin Pharmacol Ther. 2006;44(2):64–70.
   PubMedGoogle Scholar
• Majumdar AK, Howard L, Goldberg MR, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2006;46(3):291–300.
   PubMed Web of Science ®Google Scholar
• Klein S. The mini paddle apparatus- a useful tool in the early developmental stage? Experiences with immediate-release dosage forms. Dissolution Technol. 2006;13(4):6–11.
   Google Scholar
• Berlin M, Przyklenk K-H, Richtberg A, et al. Prediction of oral absorption of cinnarizine - A highly supersaturating poorly soluble weak base with borderline permeability. Eur J Pharm Biopharm. 2014;88(3):795–806.
   PubMed Web of Science ®Google Scholar
• Shono Y, Jantratid E, Janssen N, et al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm. 2009;73(1):107–114.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xia B, Sheng J, et al. Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: mechanistic investigation of food effect. AAPS PharmSciTech. 2014;15(2):400–406.
   PubMedGoogle Scholar
• Schug BS, Brendel E, Wonnemann M, et al. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur J Clin Pharmacol. 2002;58(2):119–125.
   PubMedGoogle Scholar
• Patel N, Polak S, Jamei M, et al. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS class II drug nifedipine. Eur J Pharm Sci. 2014;57:240–249.
   PubMedGoogle Scholar
• Andreas CJ, Tomaszewska I, Muenster U, et al. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine. Eur J Pharm Biopharm. 2016;105:193–202.
   PubMed Web of Science ®Google Scholar
• Paraiso RLM, Watanabe A, Andreas CJ, et al. In-vitro-in-silico investigation of the negative food effect of zolpidem when administered as immediate-release tablets. J Pharm Pharmacol. 2019;71(11):1663–1676.
   PubMedGoogle Scholar
• Andreas CJ, Pepin X, Markopoulos C, et al. Mechanistic investigation of the negative food effect of modified release zolpidem. Eur J Pharm Sci. 2017;102:284–298.
   PubMedGoogle Scholar
• Borbas E, Kadar S, Tsinman K, et al. Prediction of bioequivalence and food effect using flux- and Solubility-Based methods. Mol Pharm. 2019;16(10):4121–4130.
   PubMedGoogle Scholar
• Ikeuchi SY, Kambayashi A, Kojima H, et al. Prediction of the oral pharmacokinetics and food effects of gabapentin enacarbil. Biol Pharm Bull. 2018;41(11):1708–1715.
   PubMedGoogle Scholar
• Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. Aaps J. 2010;12(3):397–406.
   PubMed Web of Science ®Google Scholar
• Charman WN, Rogge MC, Boddy AW, et al. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J Clin Pharmacol. 1993;33(4):381–386.
   PubMedGoogle Scholar
• Lentz KA. Current methods for predicting human food effect. AAPS J. 2008;10(2):282–288.
   PubMed Web of Science ®Google Scholar
• Klein CE, Chiu Y-L, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the Soft-Gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. JAIDS. J Acquir Immune Defic Syndr. 2007;44(4):401–410.
   PubMed Web of Science ®Google Scholar
• Perlman ME, Murdande SB, Gumkowski MJ, et al. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib. Int J Pharm. 2008;351(1-2):15–22.
   PubMedGoogle Scholar
• Mitra A, Kesisoglou F. Impaired drug absorption due to high stomach pH: a review of strategies for mitigation of such effect to enable pharmaceutical product development. Mol Pharm. 2013;10(11):3970–3979.
   PubMedGoogle Scholar
• Biswas S, Benedict SH, Lynch SG, et al. Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis. BMC Med. 2012;10:57.
   PubMedGoogle Scholar
• Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988;109(6):471–473.
   PubMedGoogle Scholar
• Smelick GS, Heffron TP, Chu L, et al. Prevalence of Acid-Reducing agents (ARA) in cancer populations and ARA Drug-Drug interaction potential for molecular targeted agents in clinical development. Mol Pharm. 2013;10(11):4055–4062.
   PubMedGoogle Scholar
• Food and Drug Administration. Guidance for industury (Draft): evaluation of gastric ph-dependent drug interactions with acid-reducing agents: study design, data analysis, and clinical implications. 2021.
   Google Scholar
• Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995;39(8):1671–1675.
   PubMed Web of Science ®Google Scholar
• Russell TL, Berardi RR, Barnett JL, et al. pH-related changes in the absorption of dipyridamole in the elderly. Pharm Res. 1994;11(1):136–143.
   PubMedGoogle Scholar
• Dodd S, Kollipara S, Sanchez-Felix M, et al. Prediction of ARA/PPI Drug-Drug interactions at the drug discovery and development interface. J Pharm Sci. 2019;108(1):87–101.
   PubMedGoogle Scholar
• Kou D, Dwaraknath S, Fischer Y, et al. Biorelevant dissolution models for a weak base to facilitate formulation development and overcome reduced bioavailability caused by hypochlordyria or achlorhydria. Mol Pharm. 2017;14(10):3577–3587.
   PubMedGoogle Scholar
• Matsui K, Tsume Y, Amidon GE, et al. In vitro dissolution of fluconazole and dipyridamole in gastrointestinal simulator (GIS), predicting in vivo dissolution and Drug-Drug interaction caused by Acid-Reducing agents. Mol Pharm. 2015;12(7):2418–2428.
   PubMedGoogle Scholar
• Gu CH, Rao D, Gandhi RB, et al. Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility. J Pharm Sci. 2005;94(1):199–208.
   PubMed Web of Science ®Google Scholar
• Dickinson PA, Rmaileh RA, Ashworth L, et al. An investigation into the utility of a multi-compartmental, dynamic, system of the upper gastrointestinal tract to support formulation development and establish bioequivalence of poorly soluble drugs. AAPS J. 2012;14(2):196–205.
   PubMedGoogle Scholar
• Mitra A, Kesisoglou F, Beauchamp M, et al. Using absorption simulation and gastric pH modulated dog model for formulation development to overcome achlorhydria effect. Mol Pharm. 2011;8(6):2216–2223.
   PubMedGoogle Scholar
• Mudie DM, Murray K, Hoad CL, et al. Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. Mol Pharm. 2014;11(9):3039–3047.
   PubMed Web of Science ®Google Scholar
• Wagner JG, Nelson E. Kinetic analvsis of blood levels and urinarv excretion in the absorptive phase after single doses of drug. J Pharm Sci. 1964;53:1392–1403.
   PubMed Web of Science ®Google Scholar
• Riegelman S, Loo JC, Rowland M. Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci. 1968;57(1):117–123.
   PubMed Web of Science ®Google Scholar
• Loo JC, Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci. 1968;57(6):918–928.
   PubMedGoogle Scholar
• Kakhi M, Chittenden J. Modeling of pharmacokinetic systems using stochastic deconvolution. J Pharm Sci. 2013;102(12):4433–4443.
   PubMedGoogle Scholar
• Kakhi M, Suarez-Sharp S, Shepard T, et al. Application of an NLME-Stochastic deconvolution approach to level a IVIVC modeling. J Pharm Sci. 2017;106(7):1905–1916.
   PubMedGoogle Scholar
• Xu J, Lin Y, Boulas P, et al. Low colonic absorption drugs: risks and opportunities in the development of oral extended release products. Expert Opin Drug Deliv. 2018;15(2):197–211.
   PubMed Web of Science ®Google Scholar
• Pepin XJH, Flanagan TR, Holt DJ, et al. Justification of drug product dissolution rate and drug substance particle size specifications based on absorption PBPK modeling for lesinurad immediate release tablets. Mol Pharm. 2016;13(9):3256–3269.
   PubMedGoogle Scholar
• Hermans A, Abend AM, Kesisoglou F, et al. Approaches for establishing clinically relevant dissolution specifications for immediate release solid oral dosage forms. Aaps J. 2017;19(6):1537–1549.
   PubMedGoogle Scholar
• Food and Drug Administration. Guidance for industry: immediate release solid oral dosage forms. scale-up and postapproval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. 1995.
   Google Scholar
• Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. 2003.
   Google Scholar
• Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies submitted in NDAS or INDS - general considerations. 2014.
   Google Scholar
• Crison JR, Timmins P, Keung A, et al. Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using in silico modeling. J Pharm Sci. 2012;101(5):1773–1782.
   PubMedGoogle Scholar
• Sperry DC, Thomas SJ, Lobo E. Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug. Mol Pharm. 2010;7(5):1450–1457.
   PubMedGoogle Scholar
• Mitra A, Kesisoglou F, Dogterom P. Application of absorption modeling to predict bioequivalence outcome of two batches of etoricoxib tablets. AAPS PharmSciTech. 2015;16(1):76–84.
   PubMedGoogle Scholar
• Xu J, Naik H, Lin Y, et al. Development of a mechanistic absorption model to bridge late stage formulation for a BCS class II drug candidate. AAPS Annual Meeting and Exposition2019.
   Google Scholar
• Rebeka J, Jerneja O, Igor L, et al. PBPK absorption modeling of food effect and bioequivalence in fed state for two formulations with crystalline and amorphous forms of BCS 2 class drug in generic drug development. AAPS PharmSciTech. 2019;20(2):1–10.
   Google Scholar
• Grbic S, Parojcic J, Ibric S, et al. In vitro-in vivo correlation for gliclazide immediate-release tablets based on mechanistic absorption simulation. AAPS PharmSciTech. 2011;12(1):165–171.
   PubMed Web of Science ®Google Scholar
• Kovacevic I, Parojcic J, Homsek I, et al. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharm. 2009;6(1):40–47.
   PubMed Web of Science ®Google Scholar
• Saibi Y, Sato H, Tachiki H. Developing in vitro-in vivo correlation of risperidone immediate release tablet. AAPS PharmSciTech. 2012;13(3):890–895.
   PubMed Web of Science ®Google Scholar
• Honório T, Pinto EC, Rocha HVA, et al. In vitro-in vivo correlation of efavirenz tablets using GastroPlus. AAPS PharmSciTech. 2013;14(3):1244–1254.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2017.
   Google Scholar
• Food and Drug Administration. Waiver of In vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2000.
   Google Scholar
• European Medicines Agency. Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action. 2017.
   Google Scholar
• European Medicines Agency. ICH M9 guideline on biopharmaceutics classification system-based biowaivers 2020.
   Google Scholar
• Davit BM, Kanfer I, Tsang YC, et al. BCS biowaivers: similarities and differences among EMA, FDA, and WHO requirements. Aaps J. 2016;18(3):612–618.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry: SUPAC-MR, modified release solid oral dosage forms. 1997.
   Google Scholar
• Delvadia PR. Biowaiver Approaches for solid oral dosage forms in new drug applications. PQRI BTC Webinar 2018.
   Google Scholar
• Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420.
   PubMed Web of Science ®Google Scholar
• Khames A. Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. Drug Deliv. 2017;24(1):328–338.
   PubMed Web of Science ®Google Scholar
• Yu LX. An integrated model for determining causes of poor oral drug absorption. Pharm Res. 1999;16(12):1883–1887.
   PubMed Web of Science ®Google Scholar
• Sugano K. Fraction of dose absorbed calculation: comparison between analytical solution based on one compartment steady state approximation and dynamic seven compartment model. CBIJ. 2009;9:75–93.
   Google Scholar
• Sugano K, Terada K. Rate- and Extent-Limiting factors of oral drug absorption: theory and applications. J Pharm Sci. 2015;104(9):2777–2788.
   PubMedGoogle Scholar
• Kataoka M, Itsubata S, Masaoka Y, et al. In vitro dissolution/permeation system to predict the oral absorption of poorly water-soluble drugs: effect of food and dose strength on it. Biol Pharm Bull. 2011;34(3):401–407.
   PubMedGoogle Scholar
• Kataoka M, Sugano K, Mathews C, et al. Application of dissolution/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development. Pharm Res. 2012;29(6):1485–1494.
   PubMed Web of Science ®Google Scholar
• Sugano K. Chapter 8. Validation of mechanistic models. In: Sugano K, editor. Biopharmaceutics modeling and simulations: theory, practice, methods, and applications. 2012. Hoboken (NJ): John Wiley & Sons, Inc.
   Google Scholar
• Gao P, Shi Y. Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs. Aaps J. 2012;14(4):703–713.
   PubMed Web of Science ®Google Scholar
• Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549–2572.
   PubMed Web of Science ®Google Scholar
• Hisada N, Takano R, Takata N, et al. Characterizing the dissolution profiles of supersaturable salts, cocrystals, and solvates to enhance in vivo oral absorption. Eur J Pharm Biopharm. 2016;103:192–199.
   PubMed Web of Science ®Google Scholar
• Sun DD, Wen H, Taylor LS. Non-Sink dissolution conditions for predicting product quality and in vivo performance of supersaturating drug delivery systems. J Pharm Sci. 2016;105(9):2477–2488.
   PubMed Web of Science ®Google Scholar
• Mudie DM, Shi Y, Ping H, et al. Mechanistic analysis of solute transport in an in vitro physiological two-phase dissolution apparatus. Biopharm Drug Dispos. 2012;33(7):378–402.
   PubMedGoogle Scholar
• Mudie DM, Stewart AM, Rosales JA, et al. In Vitro-In silico tools for streamlined development of acalabrutinib amorphous solid dispersion tablets. Pharmaceutics. 2021;13(8):1257.
   PubMedGoogle Scholar
• Xu H, Shi Y, Vela S, et al. Developing quantitative in Vitro-In vivo correlation for fenofibrate Immediate-Release formulations with the biphasic Dissolution-Partition test method. J Pharm Sci. 2018;107(1):476–487.
   PubMedGoogle Scholar
• Ding X, Gueorguieva I, Wesley JA, et al. Assessment of in vivo clinical product performance of a weak basic drug by integration of in vitro dissolution tests and physiologically based absorption modeling. Aaps J. 2015;17(6):1395–1406.
   PubMedGoogle Scholar
• Polster CS, Wu S-J, Gueorguieva I, et al. Mechanism for enhanced absorption of a solid dispersion formulation of LY2300559 using the artificial stomach duodenum model. Mol Pharm. 2015;12(4):1131–1140.
   PubMedGoogle Scholar
• Psachoulias D, Vertzoni M, Goumas K, et al. Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. Pharm Res. 2011;28(12):3145–3158.
   PubMed Web of Science ®Google Scholar
• Jakubiak P, Wagner B, Grimm HP, et al. Development of a unified dissolution and precipitation model and its use for the prediction of oral drug absorption. Mol Pharm. 2016;13(2):586–598.
   PubMedGoogle Scholar
• Ruff A, Fiolka T, Kostewicz ES. Prediction of ketoconazole absorption using an updated in vitro transfer model coupled to physiologically based pharmacokinetic modelling. Eur J Pharm Sci. 2017;100:42–55.
   PubMed Web of Science ®Google Scholar
• Kaur N, Narang A, Bansal AK. Use of biorelevant dissolution and PBPK modeling to predict oral drug absorption. Eur J Pharm Biopharm. 2018;129:222–246.
   PubMed Web of Science ®Google Scholar